149 related articles for article (PubMed ID: 33280258)
1. Decreased drug resistance of bladder cancer using phytochemicals treatment.
Cho CJ; Yu CP; Wu CL; Ho JY; Yang CW; Yu DS
Kaohsiung J Med Sci; 2021 Feb; 37(2):128-135. PubMed ID: 33280258
[TBL] [Abstract][Full Text] [Related]
2. The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol.
Cho CJ; Yang CW; Wu CL; Ho JY; Yu CP; Wu ST; Yu DS
Oncol Lett; 2019 Dec; 18(6):6869-6876. PubMed ID: 31807190
[TBL] [Abstract][Full Text] [Related]
3. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Kerr M; Scott HE; Groselj B; Stratford MR; Karaszi K; Sharma NL; Kiltie AE
Clin Cancer Res; 2014 Nov; 20(21):5435-45. PubMed ID: 25224279
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
[TBL] [Abstract][Full Text] [Related]
5. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
6. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Gaivão I; Cardoso ML; Colaço A; Santos L; Oliveira P
J Toxicol Environ Health A; 2012; 75(13-15):788-99. PubMed ID: 22788366
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
An Q; Zhou L; Xu N
Biomed Pharmacother; 2018 Jul; 103():415-420. PubMed ID: 29674277
[TBL] [Abstract][Full Text] [Related]
8. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
[TBL] [Abstract][Full Text] [Related]
9. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
Muramaki M; Miyake H; Hara I; Kawabata G; Kamidono S
J Urol; 2004 Oct; 172(4 Pt 1):1485-9. PubMed ID: 15371876
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest.
Cao W; Yang Q; Yuan Z; Li H; Wang W; Xiao X; Wang Z; Liang L; Zhou P; Liu J; Hu X; Zhang B
Biochem Biophys Res Commun; 2020 Apr; 524(3):549-554. PubMed ID: 32014255
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.
Seo HK; Ahn KO; Jung NR; Shin JS; Park WS; Lee KH; Lee SJ; Jeong KC
Oncotarget; 2014 Jan; 5(2):326-37. PubMed ID: 24504118
[TBL] [Abstract][Full Text] [Related]
13. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer.
Sun M; Zhao W; Xie Q; Zhan Y; Wu B
Surg Oncol; 2015 Mar; 24(1):28-34. PubMed ID: 25434982
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
[TBL] [Abstract][Full Text] [Related]
16. Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy.
Fan P; Zhang Y; Liu L; Zhao Z; Yin Y; Xiao X; Bauer N; Gladkich J; Mattern J; Gao C; Schemmer P; Gross W; Herr I
Cell Death Dis; 2016 Jun; 7(6):e2246. PubMed ID: 27253410
[TBL] [Abstract][Full Text] [Related]
17. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells.
Takeuchi H; Mmeje CO; Jinesh GG; Taoka R; Kamat AM
Oncol Rep; 2015 Nov; 34(5):2738-44. PubMed ID: 26323344
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells.
Zhang S; Chang YY; Gong YW; Gao YJ; Guo Q; Wang YH; Zhao YL; Wang ZP
J Cell Biochem; 2019 Apr; 120(4):6347-6360. PubMed ID: 30304549
[TBL] [Abstract][Full Text] [Related]
20. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Yin L; Liu S; Li C; Ding S; Bi D; Niu Z; Han L; Li W; Gao D; Liu Z; Lu J
Tumour Biol; 2016 Sep; 37(9):12731-12742. PubMed ID: 27448305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]